Results 191 to 200 of about 118,861 (266)

Anaerobe‐Driven Inflammation and Epithelial Barrier Disruption in Genital HIV Acquisition

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Genital microbiome dysbiosis is an important risk factor for the sexual acquisition of human immunodeficiency virus (HIV) in both the male and female genital tracts. The vaginal, penile and urethral mucosae are distinct microenvironments with characteristic microbiome compositions.
Shirley Constable, Yasamin Minazadeh, Lane B. Buchanan, Henryroger Ssemunywa, Ronald M. Galiwango, Rupert Kaul, Jessica L. Prodger   +6 more
wiley   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease. [PDF]

J Enzyme Inhib Med Chem, 2019
Maseko S, Padayachee E, Maphumulo S, Govender T, Sayed Y, Maguire G, Lin J, Naicker T, Baijnath S, Gerhardus KH.   +9 more
europepmc   +1 more source

Severe HCoV‐OC43 Pneumonia in a 25‐Year‐Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation

The Clinical Respiratory Journal, Volume 20, Issue 5, May 2026.
This case reports a 25‐year‐old allo‐HCT recipient with severe HCoV‐OC43 pneumonia who responded well to off‐label nirmatrelvir/ritonavir. It is the first such report that show the drug may benefit immunocompromised patients with this infection, though further studies are needed to confirm efficacy.
Mingzhou Zhang, Ting Tang, Mingxia Zheng, Menglin Luo, Zhi Xu, Guansong Wang   +5 more
wiley   +1 more source

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. [PDF]

Antimicrob Agents Chemother, 2019
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.   +23 more
europepmc   +1 more source

A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Jacqueline Gerhart, Narayan Cheruvu, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Josué Kunjom Mfopou, Jennifer Hammond, Ravi Shankar P. Singh   +7 more
wiley   +1 more source

Enzymatic synthesis of bioactive quinolones and (thio)coumarins by fungal type III polyketide synthases

The FEBS Journal, Volume 293, Issue 9, Page 2673-2691, May 2026.
Quinolones are valuable scaffolds for drug discovery but are rare in nature. Here, we show that two fungal enzymes, AthePKS and FerePKS, can generate 2‐quinolones and two additional heteroaromatic scaffolds. Using AthePKS, we designed an artificial enzymatic cascade towards an antimicrobial quinolone from a simple precursor and implemented it in E ...
Nika Sokolova, Angelina Osipyan, Lili Zhang, Matthew R. Groves, Sandy Schmidt, Kristina Haslinger   +5 more
wiley   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source